ALGS · Company research

Aligos Therapeutics, Inc. Common Stock (ALGS): Stock News & Events

Recent company-linked news records available in the database.

RESEARCH CONTEXT

Understand the numbers

Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.

16records availableHealthcare

Stock News & Events data

Database-backed records only

16 rows
titlesummaryurlsourcepublished atsentimentsentiment scorerelevance score
ALGS Q2 2026 Earnings: Loss Per Share Narrower Than Consensus as Clinical-Stage Model Holds - Revenue Estimate Trend - https://www.dars.gov.et/ALGS Q2 2026 Earnings: Loss Per Share Narrower Than Consensus as Clinical-Stage Model Holds - Revenue Estimate Trend https://www.dars.gov.et/View source ↗https://www.dars.gov.et/Oct 6, 2026neutral00.6
Aligos Therapeutics Stock Price Forecast. Should You Buy ALGS? - StockInvest.usAligos Therapeutics Stock Price Forecast. Should You Buy ALGS? StockInvest.usView source ↗StockInvest.usOct 2, 2026neutral00.6
ALGS News | ALIGOS THERAPEUTICS INC (NASDAQ:ALGS) - ChartMillALGS News | ALIGOS THERAPEUTICS INC (NASDAQ:ALGS) ChartMillView source ↗ChartMillSep 26, 2026neutral00.6
Industry Analysts Just Made A Stunning Upgrade To Their Aligos Therapeutics, Inc. (NASDAQ:ALGS) Revenue Forecasts - Simply Wall StreetIndustry Analysts Just Made A Stunning Upgrade To Their Aligos Therapeutics, Inc. (NASDAQ:ALGS) Revenue Forecasts Simply Wall StreetView source ↗Simply Wall StreetAug 12, 2026neutral00.6
H.C. Wainwright reiterates Aligos stock rating on HBV progress - Investing.comH.C. Wainwright reiterates Aligos stock rating on HBV progress Investing.comView source ↗Investing.comAug 10, 2026neutral00.6
Aligos Therapeutics Reports $1.5 Million Q2 Net Loss and Pipeline Progress | ALGS Stock News - Quiver QuantitativeAligos Therapeutics Reports $1.5 Million Q2 Net Loss and Pipeline Progress | ALGS Stock News Quiver QuantitativeView source ↗Quiver QuantitativeAug 6, 2026neutral00.6
Aligos Therapeutics Stock Is Trending Overnight: Here's What's Going On With ALGS Stock - BenzingaAligos Therapeutics Stock Is Trending Overnight: Here's What's Going On With ALGS Stock BenzingaView source ↗BenzingaJul 7, 2026neutral00.6
China grants breakthrough status to Aligos’ HBV drug after $25M deal - Stock TitanChina grants breakthrough status to Aligos’ HBV drug after $25M deal Stock TitanView source ↗Stock TitanJul 6, 2026neutral00.6
ALGS Stock Rallies 16% After-Hours On $25M Cash Boost From China Hepatitis B Drug Deal - StocktwitsALGS Stock Rallies 16% After-Hours On $25M Cash Boost From China Hepatitis B Drug Deal StocktwitsView source ↗StocktwitsJul 6, 2026neutral00.6
Monday's after hours session: top gainers and losers - ChartMillMonday's after hours session: top gainers and losers ChartMillView source ↗ChartMillJul 6, 2026neutral00.6
Aligos Therapeutics stock jumps on $25M China licensing deal - Investing.comAligos Therapeutics stock jumps on $25M China licensing deal Investing.comView source ↗Investing.comJul 6, 2026neutral00.6
ALGS Forecast — Price Target — Prediction for 2027 - TradingViewALGS Forecast — Price Target — Prediction for 2027 TradingViewView source ↗TradingViewJun 26, 2026neutral00.6
Here's Why We're A Bit Worried About Aligos Therapeutics' (NASDAQ:ALGS) Cash Burn Situation - Simply Wall StreetHere's Why We're A Bit Worried About Aligos Therapeutics' (NASDAQ:ALGS) Cash Burn Situation Simply Wall StreetView source ↗Simply Wall StreetJun 6, 2026neutral00.6
Aligos Therapeutics (NASDAQ:ALGS) Surges After Hours on Q1 Earnings Beat - ChartMillAligos Therapeutics (NASDAQ:ALGS) Surges After Hours on Q1 Earnings Beat ChartMillView source ↗ChartMillMay 8, 2026neutral00.6
This Micro Cap Biotech Stock (ALGS) Is Tracking Its Biggest Intraday Gains In 11 Months - StocktwitsThis Micro Cap Biotech Stock (ALGS) Is Tracking Its Biggest Intraday Gains In 11 Months StocktwitsView source ↗StocktwitsApr 16, 2026neutral00.6
symbol__ Stock Quote Price and Forecast - CNNsymbol__ Stock Quote Price and Forecast CNNView source ↗CNNMar 31, 2024neutral00.6

Informational research only, not financial advice. Forecasts are uncertain and can be wrong.